IPO Trending
CORONAEQ / NSE, BSEListed

Corona Remedies Limited

Corona Remedies Limited, incorporated in August 2004, is a pharmaceutical company engaged in the development, manufacturing, and marketing of products across key therapeutic areas including women’s healthcare, cardiology, pain management, urology, and multispecialty segments. As of December 2024, its portfolio includes 67 brands covering women’s health, cardio-diabetic care, pain relief, urology, and multispecialty products such as vitamins, minerals, nutrition, gastrointestinal, and respiratory medications. The company has established a strong pan-India presence with 2,598 medical representatives across 22 states, ensuring deep engagement with healthcare professionals and hospitals. It operates two manufacturing facilities in Gujarat, supporting its production and quality-focused growth strategy in the Indian Pharmaceutical Market.

₹1,008 - ₹1,062144.49x sub
Listed Price1470.00
Listing Gain+38.42%
Review-Analyst Consensus Verdict

Apply

Canara Bank Securities Ltd recommendation is Apply.

Apply
1286%
May Apply
17%
Neutral
00%
Avoid
00%
Not Rated
17%
Brokers / Analysts Review
ReviewerRecommendationReport
Canara Bank Securities LtdApplyDownload
Capital MarketMay ApplyDownload
Swastika Investmart LtdApplyDownload
Lakshmishree Investment & Securities LimitedApplyDownload
Anand RathiApplyDownload
Bajaj Financial Securities LimitedNot RatedDownload
BP Equities (BP Wealth)ApplyDownload
GEPL Capital LimitedApplyDownload
Marwadi Shares and Finance LimitedApplyDownload
Nirmal BangApplyDownload
SBICAP Securities LimitedApplyDownload
Sushil Finance LimitedApplyDownload
Swastika Investmart LtdApplyDownload
Ventura Securities LimitedApplyDownload